Trial Profile
Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II, and VI
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Mar 2023
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Mucopolysaccharidosis I; Mucopolysaccharidosis II; Mucopolysaccharidosis VI
- Focus Therapeutic Use
- 20 Mar 2023 Planned End Date changed from 1 Feb 2023 to 1 Jun 2026.
- 20 Mar 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.
- 20 Mar 2023 Status changed from recruiting to active, no longer recruiting.